Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 71

1.
2.

The role of selective estrogen receptor modulators in the prevention of breast cancer: comparison of the clinical trials.

Martino S, Costantino J, McNabb M, Mershon J, Bryant K, Powles T, Secrest RJ.

Oncologist. 2004;9(2):116-25. Review.

3.

Selective estrogen receptor modulators (SERMs) and retinoids in breast cancer chemoprevention.

Zujewski J.

Environ Mol Mutagen. 2002;39(2-3):264-70. Review.

PMID:
11921197
4.

Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer.

Gail MH, Costantino JP, Bryant J, Croyle R, Freedman L, Helzlsouer K, Vogel V.

J Natl Cancer Inst. 1999 Nov 3;91(21):1829-46. Review. Erratum in: J Natl Cancer Inst 2000 Feb 2;92(3):275.

PMID:
10547390
5.

Tamoxifen, raloxifene and the prevention of breast cancer.

Bentrem DJ, Craig Jordan V.

Minerva Endocrinol. 2002 Jun;27(2):127-39. Review.

PMID:
11961504
6.

The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer.

Howell SJ, Johnston SR, Howell A.

Best Pract Res Clin Endocrinol Metab. 2004 Mar;18(1):47-66. Review.

PMID:
14687597
7.

Tamoxifen, screening and new oestrogen receptor modulators.

Neven P, Vergote I.

Best Pract Res Clin Obstet Gynaecol. 2001 Jun;15(3):365-80. Review.

PMID:
11476559
8.

What would be the properties of an ideal SERM?

Anthony M, Williams JK, Dunn BK.

Ann N Y Acad Sci. 2001 Dec;949:261-78. Review.

PMID:
11795362
9.

[Additional effect of SERM: mammary gland].

Kurebayashi J.

Clin Calcium. 2004 Oct;14(10):47-51. Review. Japanese.

PMID:
15577131
10.

Prevention of hormone-related cancers: breast cancer.

Dunn BK, Wickerham DL, Ford LG.

J Clin Oncol. 2005 Jan 10;23(2):357-67. Review.

PMID:
15637398
11.

Breast cancer risk management.

Reeder JG, Vogel VG.

Clin Breast Cancer. 2007 Dec;7(11):833-40. doi: 10.3816/CBC.2007.n.047. Review.

PMID:
18269772
12.

Endocrine manipulation in advanced breast cancer: recent advances with SERM therapies.

Johnston SR.

Clin Cancer Res. 2001 Dec;7(12 Suppl):4376s-4387s; discussion 4411s-4412s. Review.

PMID:
11916228
13.
14.

The effect of SERMs on the endometrium.

Goldstein SR.

Ann N Y Acad Sci. 2001 Dec;949:237-42. Review.

PMID:
11795358
15.

Breast cancer prevention with selective estrogen receptor modulators: a perspective.

Pritchard KI.

Ann N Y Acad Sci. 2001 Dec;949:89-98. Review.

PMID:
11795385
16.

Prevention of breast cancer: current state of the science and future opportunities.

Uray IP, Brown PH.

Expert Opin Investig Drugs. 2006 Dec;15(12):1583-600. Review.

PMID:
17107283
17.

The past, present, and future of selective estrogen receptor modulation.

Jordan VC.

Ann N Y Acad Sci. 2001 Dec;949:72-9. Review.

PMID:
11795383
18.

Rationale for using raloxifene to prevent both osteoporosis and breast cancer in postmenopausal women.

Lee WL, Chao HT, Cheng MH, Wang PH.

Maturitas. 2008 Jun 20;60(2):92-107. doi: 10.1016/j.maturitas.2008.04.009. Epub 2008 Jun 4. Review.

PMID:
18534794
19.

Toremifene: an evaluation of its safety profile.

Harvey HA, Kimura M, Hajba A.

Breast. 2006 Apr;15(2):142-57. Epub 2005 Nov 9. Review.

PMID:
16289904
20.

Prevention of breast cancer using SERMs and aromatase inhibitors.

Strassmer-Weippl K, Goss PE.

J Mammary Gland Biol Neoplasia. 2003 Jan;8(1):5-18. Review.

PMID:
14587860

Supplemental Content

Support Center